



## Gallium 68 Radiochemistry and Labelling Strategies

Guest Editors:

**Dr. Giuseppe Carlucci**

UCLA Molecular and Medical  
Pharmacology Department,  
University of California, Los  
Angeles, CA 90095, USA

**Dr. Irina Velikyan**

Department of Surgical Science,  
Uppsala University, 751 85  
Uppsala, Sweden

Deadline for manuscript  
submissions:

**closed (20 February 2024)**

### Message from the Guest Editors

Gallium-68 ( $^{68}\text{Ga}$ ) has proven to be an essential radionuclide for the fundamental biological studies, development of radiopharmaceuticals for clinical use, and drug development due to its favorable physical and chemical properties as well as ready availability from a generator system. The interest in  $^{68}\text{Ga}$  has increased tremendously in the recent decade as a result of wide clinical applications in combination with positron emission tomography (PET) and its connection to the subsequent radiotherapy in the context of (radio)theranostics. The crucial advantages of  $^{68}\text{Ga}$  are its availability from a  $^{68}\text{Ge}/^{68}\text{Ga}$  generator and its labelling chemistry amenable to the automation and kit-type preparation. Moreover, it can nowadays also be produced with a cyclotron using solid and liquid targets.

This Special Issue will focus on the development of  $^{68}\text{Ga}$  radiopharmaceuticals and their applications. The subject may range from radioactive isotope production, labeling chemistry and quality control to preclinical evaluation and clinical trials and clinical routine application. The (radio)theranostic and pharmacokinetic modelling studies are also of strong interest.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)